A predictive tool considering disease duration, age at disease onset, age, and Expanded Disability Status Scale score estimated patients’ risk of transition to secondary progressive multiple sclerosis ...
High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback